Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 8/20 | 0.37 |
| ▸ | FLT1 | P17948 | 6/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.37 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26985103 | 0.92 | NUDT1 (0.40) | NUDT1KDRFLT1FGFR1TRPM5 | |
| SCHEMBL26985138 | 0.90 | NUDT1 (0.42) | NUDT1KDRFLT1FGFR1TRPM5 | |
| SCHEMBL30746708 | 0.90 | NUDT1 (0.42) | NUDT1KDRFLT1FGFR1TRPM5 | |
| SCHEMBL30746421 | 0.89 | NUDT1 (0.41) | NUDT1KDRFLT1FGFR1TRPM5 | |
| SCHEMBL26984929 | 0.89 | NUDT1 (0.41) | NUDT1KDRFLT1FGFR1TRPM5 | |
| SCHEMBL30746604 | 0.89 | DHFR (0.34) | CSF1RDHFRMPO | |
| SCHEMBL30746454 | 0.89 | KDM4E (0.35) | NUDT1KDRFLT1CSF1RDHFR | |
| SCHEMBL26984875 | 0.89 | KDM4E (0.35) | NUDT1KDRFLT1CSF1RDHFR | |
| SCHEMBL26985336 | 0.89 | DHFR (0.34) | CSF1RDHFRMPO | |
| SCHEMBL30746407 | 0.88 | KDR (0.41) | NUDT1KDRFLT1FGFR1TRPM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| CN-120129678-A | Mitogen-activated protein kinase (MEK) inhibitors | 耐斯泰德医疗公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4551558-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | Nested Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024010925-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010925-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | MAPK6, MAPK3, MAPK1 | NUDT1 1810/4885KDR 818/4885FLT1 3167/4885 |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | BRAF, MAP3K1, MAP3K5 | NUDT1 2559/4885KDR 911/4885FLT1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.